scispace - formally typeset
X

Xia Shen

Researcher at Harvard University

Publications -  8
Citations -  344

Xia Shen is an academic researcher from Harvard University. The author has contributed to research in topics: Medicine & Microglia. The author has an hindex of 2, co-authored 3 publications receiving 275 citations. Previous affiliations of Xia Shen include Fudan University.

Papers
More filters
Journal ArticleDOI

Selective Anesthesia-induced Neuroinflammation in Developing Mouse Brain and Cognitive Impairment

TL;DR: The findings suggest the cellular basis and the potential prevention and treatment strategies for anesthesia-induced cognitive impairment, which may ultimately lead to safer anesthesia care and better postoperative outcomes for children.
Journal ArticleDOI

Definition of a mouse microglial subset that regulates neuronal development and proinflammatory responses in the brain

TL;DR: Analysis of the contribution of OPN to the intrinsic functions of this CD11c+ microglial subset indicates that OPN is required for subset stability and the execution of phagocytic and proinflammatory responses, in part through OPN-dependent engagement of the αVβ3-integrin receptor.
Journal ArticleDOI

RNA interference-mediated silencing of BACE and APP attenuates the isoflurane-induced caspase activation

TL;DR: It is shown for the first time that treatment with BACE and APP siRNAs can decrease levels of BACE, full-length APP, and APP c-terminal fragments, and the treatment attenuates the Aβ levels and the isoflurane-induced caspase-3 activation.
Journal ArticleDOI

Definition of the contribution of an Osteopontin-producing CD11c+ microglial subset to Alzheimer's disease.

TL;DR: The authors identified a pathogenic microglial subset which expressed the CD11c surface marker as the sole producer of Osteopontin (OPN) in the 5XFAD mouse model of Alzheimer's disease.
Journal ArticleDOI

Antibody-mediated blockade of the IL23 receptor destabilizes intratumoral regulatory T cells and enhances immunotherapy

TL;DR: A pathway to interfere with regulatory T cell stability by disrupting the expression of the interleukin 23 receptor is reported, leading to increased production of gamma-interferon and more efficient antitumor immune responses.